BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that it has completed patient enrollment in a phase IIb clinical trial of lintuzumab (SGN-33) in combination with low-dose cytarabine chemotherapy for patients with acute myeloid leukemia (AML).
